LY3938577

Phase 2Small molecule

Eli Lilly

LY3938577 is one of 18 small molecule programs targeting Diabetes Mellitus, Type 2. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes Mellitus, Type 2Active, not recruiting

Diabetes Mellitus, Type 2Phase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Diabetes Mellitus, Type 2

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

15 2

Farxiga

AstraZeneca

Approved

3 3

Actos

Takeda

Approved

2 4

Trulicity

Eli Lilly

Approved

2 5

Mounjaro

Eli Lilly

Approved

2 6

Jardiance

Boehringer Ingelheim

Approved

4 7

Glucophage

EMD Serono

Approved

3 8

Januvia

ZZydus Therapeutics Inc.

Approved

2 9

Invokana

WWim Janssens

Approved

1 10

Tradjenta

Boehringer Ingelheim

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diabetes Mellitus, Type 2

NCT07215312

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06132126·66 enrolled

Type 1 Diabetes Mellitus1 trial

A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06280703·121 enrolled

Diabetes Mellitus, Type 21 trial

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07215312·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LY3938577. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3938577 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3938577. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY3938577

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

Type 1 Diabetes Mellitus1 trial

Diabetes Mellitus, Type 21 trial

References

Drug Info

Quick Facts

Related News